# Use of Dapagliflozin to Reduce Burden of Atrial Fibrillation in Patients Undergoing Catheter Ablation of Symptomatic Atrial Fibrillation

> **NCT04792190** · PHASE4 · COMPLETED · sponsor: **University of Rochester** · enrollment: 25 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** dapagliflozin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04792190
- **Lead sponsor:** University of Rochester
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-27
- **Primary completion:** 2023-03-31
- **Final completion:** 2023-06-30
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2024-12-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04792190

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04792190, "Use of Dapagliflozin to Reduce Burden of Atrial Fibrillation in Patients Undergoing Catheter Ablation of Symptomatic Atrial Fibrillation". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04792190. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*